Multiple Sclerosis
Conditions
Keywords
Multiple Sclerosis, Betaseron-Prograf, patients of Multiple Sclerosis, Secondary Progressive type, Relapsing-Remitting type
Brief summary
The purpose of the study is to evaluate the safety and tolerability of a combination of interferon beta 1-b (Betaseron®) and tacrolimus (Prograf®) in patients suffering from multiple sclerosis (MS) who have failed treatment with currently approved drugs for MS Prograf is an immunosuppressant that weakens the immune reactions responsible to protect the organism against infections. It is currently available on the market for patients who have received an organ transplant, to prevent rejection. Because of its effect on the immune system, theoretically, Prograf should exert a significant effect in MS. It has been tried in a small number of MS patients at a lower dose than the one used in organ transplant, however the results of the study did not allow to draw definite conclusions on its safety and efficacy in MS. Betaseron is approved in Canada for the reduction of the frequency of relapses in patients with relapsing-remitting MS and for the slowing of progression and reduction of the frequency of relapses in patients with secondary-progressive MS. The combination of Betaseron and Prograf may result in an additive effect or an increase in the actions of the drugs. However, the combination of the two drugs has never been studied. The aim of this study is to see how well the combination of Betaseron and Prograf is tolerated by patients with MS. The side effects of the treatment, if any, will be followed. In addition, the efficacy of the combination will be evaluated.
Interventions
DRUGInterferon beta-1b and Tacrolimus
Sponsors
Clinique de sclérose en plaques et neuromusculaire de l'Outaouais
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* relapsing-remitting or secondary-progressive multiple sclerosis * patients who have failed treatment with approved immunomodulator drugs (having experienced same or higher annual relapse rate or having experinced progression on the EDSS scale) * Expanded Disability Status Scale (EDSS) score less than 7.0
Exclusion criteria
* any of the following conditions: diabetes mellitus, uncontrolled hypertension, active infection or viral diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety and tolerability | — |
| relapse rate | — |
| number of T2 godolinium enhencing lesions on MRI | — |
| expanded disease severity score (EDSS) | — |
| multiple sclerosis functional composite(MSFC) | — |
Countries
Canada
Outcome results
None listed